Geode Capital Management LLC Makes New $4.13 Million Investment in Rapport Therapeutics (NASDAQ:RAPP)

Geode Capital Management LLC acquired a new stake in Rapport Therapeutics (NASDAQ:RAPP) in the 3rd quarter, Holdings Channel reports. The firm acquired 201,748 shares of the company’s stock, valued at approximately $4,133,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Values First Advisors Inc. acquired a new position in Rapport Therapeutics during the 3rd quarter valued at $31,000. BNP Paribas Financial Markets bought a new position in shares of Rapport Therapeutics during the 3rd quarter worth about $34,000. SG Americas Securities LLC bought a new position in shares of Rapport Therapeutics during the 3rd quarter worth about $101,000. Sandia Investment Management LP acquired a new position in shares of Rapport Therapeutics during the second quarter valued at about $116,000. Finally, MetLife Investment Management LLC bought a new stake in shares of Rapport Therapeutics in the third quarter valued at about $117,000.

Rapport Therapeutics Stock Performance

Shares of RAPP opened at $19.48 on Monday. The firm’s 50-day moving average price is $21.51. Rapport Therapeutics has a 12-month low of $16.55 and a 12-month high of $29.74.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.